Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich to Market Protein Arrays Made by Procognia

NEW YORK, Nov. 9 (GenomeWeb News) - Sigma-Aldrich will market human protein arrays developed by Procognia, the companies said today.

Procognia has developed a tag technology to create arrays of biologically related human proteins that retain their native functions in the array format, the companies said. The first array will contain wild type human p53 and its germline SNP variants.


Procognia's SNP-variant proteins will enable researchers to investigate the mechanism of cancer progression on many proteins in parallel, the company said.


Additional protein arrays, expected to launch "in the coming months," will contain "selected sets of biologically related human proteins including collections of proteins associated with key diseases including cancer and signal transduction," according to a statement.


Financial terms of the exclusive collaboration were not disclosed.


Separately, Sigma said it has declared a quarterly cash dividend of $.17 per share. The dividend is payable on Dec. 15 to shareholders of record on Dec. 1, 2004.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.